Front line to support Member States
Regional Revolving Funds
What are the RRF?

**Goals**

- **Accessibility**
  Equitable access to hard-to-procure & new technologies

- **Affordability**
  Cost-effective technologies and negotiation leverage

- **Availability**
  Consistent and reliable supply of right technologies

- **Assurance of Quality**
  International quality standards
Regional Revolving Funds

- Vaccines
- Medicines
- Diagnostics
- Medical Devices
- Vector Control
- Cold chain equipment
- Safe Injection Devices
What do the RRFs do?

Technical cooperation mechanisms for PAHO Member States and participating entities to improve access of vaccines, essential medicines and strategic health supplies in the Americas.

- Reduces costs through economies of scale and innovative procurement strategies.
- Strengthens national capacities in demand planning, supply chain management, and appropriate use of procured products.
- Ensures continuous and timely availability of supplies.
- Guarantees quality vaccines, medicines and public health supplies that meet PAHO/WHO standards.
- Supports Member States’ public health programs and application of pertinent PAHO/WHO regulatory mandates.
- Provides financial options to purchase essential medicines and supplies, such as the credit line.
Market Shaping: Strategic Fund at work

Epidemiological Surveillance

Treatment Protocols

nEML Alignment

Intellectual Property

Rational Selection

Supply Landscape Surveillance

Quality Assurance

Price Evaluations

Supplier Relationship Management

Regional Supply Resilience

Demand Shaping

Supply Shaping

Access + Availability + Affordability

Demand Planning

Supply Assurance
Opportunities Identified: HIV Protocol Migration

Total Annual Savings USD 537,837

<table>
<thead>
<tr>
<th>Country X</th>
<th>SF Price</th>
<th>Annual Savings</th>
<th>Monthly Savings</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDF/EFV/EZ</td>
<td>USD 42,696</td>
<td>▼ USD 242,832</td>
<td>USD 22,460</td>
</tr>
<tr>
<td>TLD SF</td>
<td>USD 11,206</td>
<td>▼ USD 111,681</td>
<td>USD 1,900</td>
</tr>
<tr>
<td>TDF/FTC/EZ</td>
<td>USD 3,874</td>
<td>▼ USD 32,099</td>
<td>USD 1,200</td>
</tr>
<tr>
<td>TDF/FTC+NVP</td>
<td>USD 10,075</td>
<td>▼ USD 109,444</td>
<td>USD 1,200</td>
</tr>
<tr>
<td>ABC+3TC+EZ</td>
<td>USD 955</td>
<td></td>
<td>USD 955</td>
</tr>
<tr>
<td>3TC/ATZ+EFZ</td>
<td>USD 4,376</td>
<td></td>
<td>USD 895</td>
</tr>
<tr>
<td>TLD SF</td>
<td>USD 1,200</td>
<td></td>
<td>USD 955</td>
</tr>
</tbody>
</table>
Pooled Procurement Benefits: Economies of Scale

**Trastuzumab 420 mg - 440 mg INJ**

- **Unit Price**
  - Country 1: $5,000
  - Country 2: $2,900
  - Country 3: $1,800
  - Country 4: $1,200
  - Country 5: $700
  - Country 6: $550
  - Country 7: $495
  - PAHO SF: $445

- **Price Difference**

**Docetaxel 80 mg INJ**

- **Unit Price**
  - Country 1: $67.50
  - Country 2: $37.08
  - Country 3: $30.70
  - Country 4: $30.56
  - Country 5: $26.59
  - Country 6: $20.38
  - Country 7: $10.13
  - PAHO SF: $6.88

Source: Public data from country purchases. Country legend may vary across graphs.
Regional Manufacturing Platform

How PAHO through RRFs orchestrate the process?

- Facilitate the discussion of product selection: Portfolio optimization
- Regional demand forecasting and planning
- Capacity building around regulatory strengthening and harmonization.
- Supply Chain Management strengthening
- Risk Sharing – across countries and usage of regional hub and safety stock